Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GT 2227

Drug Profile

GT 2227

Latest Information Update: 03 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gliatech (CEASED)
  • Class Antidepressants; Antihistamines; Neuroprotectants; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 02 Feb 2017 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 23 Dec 2003 Suspended - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
  • 24 Aug 2001 No-Development-Reported for Attention-deficit hyperactivity disorder in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top